drugset / Trial / NCT06034314
Oral Dronabinol-HIV
Phase 1
Active not recruiting
160 enrolled
Yale University
National Institute on Drug Abuse (NIDA) · collab
Non-randomizedParallel-groupOpen-labelOther
Summary
The purpose of this study is to define the mechanisms of cannabis on the genome of people with HIV who use cannabis. The investigator aims to better understand the effect of Dronabinol on immune and inflammatory functions, and whether these changes are HIV-status dependent. This research may better inform public health policy regarding cannabis use. Depending on the results, additional studies may also build upon this research to develop more effective and specific treatments for cannabis use associated disorders.
Timeline
- Start
- 2023-09-21
- Primary completion
- 2026-10-01
- Completion
- 2028-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dronabinol | Other / unclassified | 20 mg | Oral |